Altimmune Inc ALT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD

After Hours: Last | 05/10/24 EDT

7.32

+0.10 (+1.39%)

Volume

51,352

7.22

-0.50 (-6.48%)

Volume

2,964,878

52 week range

2.09 - 14.84

Open7.65
Day High7.81
Day Low7.06
Prev Close7.72
52 Week High14.84
52 Week High Date02/28/24
52 Week Low2.09
52 Week Low Date10/23/23

Key Stats

Market Cap511.864M
Shares Out70.90M
10 Day Average Volume3.16M
Dividend-
Dividend Yield-
Beta0.10
YTD % Change-35.82

KEY STATS

Open7.65
Day High7.81
Day Low7.06
Prev Close7.72
52 Week High14.84
52 Week High Date02/28/24
52 Week Low2.09
52 Week Low Date10/23/23
Market Cap511.864M
Shares Out70.90M
10 Day Average Volume3.16M
Dividend-
Dividend Yield-
Beta0.10
YTD % Change-35.82

RATIOS/PROFITABILITY

EPS (TTM)-1.64
P/E (TTM)-4.39
Fwd P/E (NTM)-6.80
EBITDA (TTM)-83.033M
ROE (TTM)-46.63%
Revenue (TTM)425,999.999
Gross Margin (TTM)-
Net Margin (TTM)-20,762.21%
Debt To Equity (MRQ)-

EVENTS

Earnings Date08/08/2024(est)
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Latest On Altimmune Inc

New rivals could threaten Novo Nordisk, Eli Lilly's weight loss drug dominance May 7, 2024CNBC.com
Lightning Round: The cycle could be turning against CVR Energy, says Jim CramerMay 6, 2024CNBC.com
Cramer's Lightning Round: Quanta Services is 'terrific'May 6, 2024CNBC.com

Content From Our Affiliates

Buy Rating Affirmed for Altimmune on Pemvidutide’s Potential and Strategic AdvancementsMay 10, 2024TipRanks
Altimmune price target lowered to $24 from $25 at JMP SecuritiesMay 10, 2024TipRanks
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Evolent Health (EVH) and Cormedix (CRMD)May 10, 2024TipRanks
Altimmune reports Q1 EPS (34c), consensus (37c)May 9, 2024TipRanks
Altimmune Announces First Quarter 2024 Financial Results and Provides a Business UpdateMay 9, 2024TipRanks

Profile

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing...

Mitchel Sayare Ph.D.

Independent Chairman of the Board

Vipin Garg Ph.D.

President, Chief Executive Officer, Director

Richard Eisenstadt

Chief Financial Officer

Address

910 Clopper Rd Ste 201S

Gaithersburg, MD

20878-1361

United States

https://altimmune.com/

Top Peers

SYMBOL	LAST	CHG	%CHG
NKTX Nkarta Inc	6.25	-0.05	-0.79%
KALV Kalvista Pharmaceuticals Inc	12.08	-0.01	-0.08%
ALLO Allogene Therapeutics Inc	2.76	-0.10	-3.50%
ATXS Astria Therapeutics Inc	9.73	-0.44	-4.33%
CMPS Compass Pathways PLC	7.86	-0.68	-7.96%